Categories: NewsPatient Care

DeepSight™ Technology Receives First FDA 510(k) Clearance for NeedleVue™ LC1 Ultrasound System

Bringing Clarity and Confidence to Ultrasound-Guided Interventional Procedures

SANTA CLARA, Calif., Aug. 13, 2025 /PRNewswire/ — DeepSight Technology, a medical imaging pioneer, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its NeedleVue LC1 Ultrasound System.

This clearance marks an important step forward in DeepSight’s development of its NeedleVue and OnPoint technologies that will work in tandem with the NeedleVue LC1 Ultrasound System to transform image-guided procedures. “This is a foundational milestone in our mission to deliver crystal clear, sub millimeter level guidance inside the body,” said Nader Sadrzadeh CEO of DeepSight. “We have developed the next generation sensor technology for enhancing ultrasound where it what matters most—clear visualization, procedural efficiency, and user confidence. We’re just getting started and look forward to building on this achievement as we expand our clinical and commercial momentum in the months ahead.”

To learn more about the NeedleVue LC1 Ultrasound System and DeepSight’s mission to advance procedural ultrasound, visit www.deepsight.com.

Visit DeepSight at the upcoming LSI’25 Europe meeting in London September 7th – 11th and Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference in Barcelona, September 13–17, to experience NeedleVue technology firsthand.

About DeepSight Technology
DeepSight Technology, founded in 2019 by Nader Sadrzadeh, Lan Yang, and Anand Chandrasekher, is built on a bold vision — to revolutionize medical imaging through proprietary sensing technology. With offices in the San Francisco Bay Area and Clayton, Missouri, DeepSight aims to extend the capabilities of ultrasound across diagnostic, therapeutic, surgical, and interventional applications —advancing patient care and improving public health worldwide. Our next-generation sensor technology will transform ultrasound, with the goal to deliver exceptional clarity, pinpoint precision, and unparalleled confidence for clinicians in every procedure.

View original content to download multimedia:https://www.prnewswire.com/news-releases/deepsight-technology-receives-first-fda-510k-clearance-for-needlevue-lc1-ultrasound-system-302529247.html

SOURCE DeepSight Technology, Inc.

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago